解氏肝癌2号方对肝癌H22荷瘤小鼠作用的研究  

Study on Xie's liver cancer prescription NO.2 on mice with H22 liver cancer

作　　者：崔佳[1] 朱成功[1] 赵莹莹[2] 解建国[2] 

机构地区：[1]大连医科大学附属第二医院,辽宁大连116027 [2]辽宁省大连市中心医院,辽宁大连116033

出　　处：《现代中西医结合杂志》2014年第33期3655-3657,3661,共4页Modern Journal of Integrated Traditional Chinese and Western Medicine

摘　　要：目的研究解氏肝癌2号方对肝癌H22荷瘤小鼠的抗肿瘤及免疫调节作用。方法建立H22肝癌小鼠模型,随机分为模型组、解氏肝癌2号方组、中药半枝莲组和白细胞介素-2(IL-2)组共4组,每组10只,并予第2天始给予相应药物灌胃。第15天处死小鼠,取出肿瘤,称取瘤质量,计算抑瘤率、胸腺指数、脾指数等指标,并通过免疫组化的方法检测凋亡相关蛋白Bcl-2和Bax的表达情况。结果 1解氏肝癌2号方组与IL-2组体质量增加更为明显。2解氏肝癌2号方组的抑瘤率与中药半枝莲组相仿,二者均显著高于IL-2组。3解氏肝癌2号方组与IL-2组的胸腺指数和脾脏指数无明显差异,均明显高于中药半枝莲组及模型组。4解氏肝癌2号方组Bcl-2水平与中药半枝莲组相仿,低于模型组和IL-2组,模型组最高;而Bax水平正好相反,解氏肝癌2号方组与中药半枝莲组均高于模型组和IL-2组,模型组最低。结论解氏肝癌2号方能明显改善小鼠的一般生活状态,增加小鼠体质量,对肿瘤有明显抑制作用,并且下调肝癌H22荷瘤小鼠的凋亡相关蛋白Bcl-2的表达,上调Bax的表达,能够明显改善机体免疫功能,减轻恶性肿瘤对机体的损害,减轻病痛,使人体与癌肿长期共存,互不侵犯。本实验为临床"带瘤生存"理念提供了坚实的理论基础。Objective It is to observe the anti -tumor and immunoregulation effect of Xie’s liver cancer prescription NO. 2 in mice with H22 liver cancer.Methods The H22 liver cancer mice model were established and divided into 4 groups randomly, including model group （group A）, Xie’s liver cancer prescription NO.2 group （group B）, herba scutellariae barbatae group （group C） and IL -2 group （group D）, 10 mouse in each group.All animal were given corresponding medicine by stomach start on the next day.On the 15th day, the mouse were killed and got the tumor out to weigh the tumor, calculate the tumor inhibition rate, thymus index, spleen index and other related indexes, and the expression of Bcl -2 and Bax were detected by immunohistochemistry.Results ①The weight of body were increased more obviously in group B and group D.②The tumor inhibition rate of group B was similar as that of group C, and both were higher than that of group D.③There were no significant differences in thymus index and spleen index between group B and group D, but they were both significantly higher than that of group A and group C.④The Bcl -2 content of group B was similar as that of group C, and both were lower than that of group A and group D.The content of Bcl -2 of group A was the highest.While the result of Bax content was the opposite, both data of group B and group C were higher than the other two groups’ and the content of group A was the lowest. Conclusion Xie’s liver cancer prescription NO.2 can improve the survival situation of tumor -bearing mice, increase the body weight of mice and effectively inhibit the tumor.Also, it can lower the Bcl -2 gene expression of tumor -bearing mice with liver cancer H22 and upper the Bax gene expression.It can significantly improve the immune function, alleviate the damage to the body of malignant tumor, and make human body and the cancer long -term coexistence, mutual non -aggression. This experiment provides a solid theoretical basis for the clinical ＂survival＂ concept.

关 键 词：原发性肝癌 解氏肝癌2号方 H22细胞株 BCL-2 BAX 

分 类 号：R-332[医药卫生]